EUVIMEDEUVIMED entdecken
Crossref

Quetiapine in Bipolar Disorder: Clinical Pharmacology, Receptor Pharmacology, And The Mechanistic Basis of Its Antidepressant And Mood-Stabilizing Effects

Michel Bourin*

Psychiatry and Psychological Disorders · 02.11.2026 · 5 (2)

DOI: 10.58489/2836-3558/048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychiatry and Psychological Disorders, online erschienen am 02.11.2026. Verfasst von Michel Bourin*.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quetiapine is an atypical antipsychotic with established efficacy across several phases of bipolar disorder, including acute bipolar depression, acute mania, and maintenance treatment. Its clinical profile is unusual among antipsychotic drugs because clinically relevant antidepressant activity occurs at doses that do not simply correspond to conventional high-level dopamine D2 receptor blockade. The pharmacology of quetiapine is further complicated by the formation of the active metabolite N-desalkylquetiapine (norquetiapine), whose receptor and transporter profile differ substantially from that of the parent compound. Consequently, the therapeutic effects of quetiapine are better conceptualized as the result of a pharmacologically integrated parent-drug/metabolite system rather than because of D2 antagonism alone. The present review examines the clinical pharmacology of quetiapine in bipolar disorder, with particular emphasis on the mechanistic basis of its antidepressant effects. Quetiapine antagonizes dopamine D2 and serotonin 5-HT2A receptors and interacts with histamine H1, α1-adrenergic and muscarinic receptors. Norquetiapine has relatively greater affinity for several of these targets and, importantly, inhibits the norepinephrine transporter (NET) and exhibits partial agonist activity at 5-HT1A receptors. Human positron-emission tomography studies provide evidence that clinically relevant quetiapine exposure produces measurable NET occupancy, supporting a role for noradrenergic modulation in the antidepressant response. Preclinical data further suggests interactions with serotonergic, dopaminergic and noradrenergic neurotransmission, while proposed effects on intracellular signalling, neuroplasticity and circadian regulation remain less firmly established. Clinical trials consistently demonstrate that quetiapine is superior to placebo in acute bipolar depression, with antidepressant effects detectable during the first week of treatment. Both immediate-release and extended-release formulations have demonstrated efficacy, while higher doses have consistently produced greater antidepressant benefit than approximately 300 mg/day in acute bipolar depression. Quetiapine is also effective in relapse prevention, particularly for depressive recurrence, although interpretation of maintenance trials must account for enrichment and discontinuation designs. The principal limitation of quetiapine is its tolerability profile, particularly somnolence, sedation, orthostatic hypotension, weight gain and metabolic abnormalities. These adverse effects can be understood partly through its receptor pharmacology, especially H1, α1-adrenergic and muscarinic antagonism. Overall, quetiapine represents a pharmacologically complex treatment whose antidepressant activity cannot be adequately explained by its antipsychotic D1 antagonism. The most coherent current model involves complementary serotonergic, noradrenergic and dopaminergic effects generated by the parent drug and norquetiapine, while acknowledging that the precise molecular mechanism responsible for clinical antidepressant and mood-stabilizing efficacy remains unresolved.

Zitieren

APA

Bourin*, M. (2026). Quetiapine in Bipolar Disorder: Clinical Pharmacology, Receptor Pharmacology, And The Mechanistic Basis of Its Antidepressant And Mood-Stabilizing Effects. Psychiatry and Psychological Disorders, 5(2). https://doi.org/10.58489/2836-3558/048

Vancouver

Bourin* M. Quetiapine in Bipolar Disorder: Clinical Pharmacology, Receptor Pharmacology, And The Mechanistic Basis of Its Antidepressant And Mood-Stabilizing Effects. Psychiatry and Psychological Disorders. 2026;5(2). doi:10.58489/2836-3558/048

BibTeX
@article{Bourin2026,
  author = {Bourin*, Michel},
  title = {Quetiapine in Bipolar Disorder: Clinical Pharmacology, Receptor Pharmacology, And The Mechanistic Basis of Its Antidepressant And Mood-Stabilizing Effects},
  journal = {Psychiatry and Psychological Disorders},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.58489/2836-3558/048}
}
Kostenlos starten →